Who Exports Salmeterol from India — 148 Suppliers Behind a $72.8M Market
India's salmeterol export market is supplied by 148 active exporters who collectively shipped $72.8M across 7,006 shipments. CIPLA LIMITED leads with a 76.5% market share, followed by HETERO LABS LIMITED and MEDISPRAY LABORATORIES PRIVATE LIMITED. The top 5 suppliers together control 92.5% of total export value, reflecting a concentrated market structure.
Top Salmeterol Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading salmeterol exporter from India, holding a 76.5% share of the $72.8M market across 7,006 shipments from 148 exporters. The top 5 suppliers — CIPLA LIMITED, HETERO LABS LIMITED, MEDISPRAY LABORATORIES PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED, VAMSI PHARMA PRIVATE LIMITED — collectively control 92.5% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (76.5%), HETERO LABS LIMITED (8.8%), MEDISPRAY LABORATORIES PRIVATE LIMITED (4.3%), ZYDUS LIFESCIENCES LIMITED (1.5%), VAMSI PHARMA PRIVATE LIMITED (1.5%).
Top Salmeterol Exporters from India
Ranked by export value · 148 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED SAFLU 250 INHALER (SALMETEROLSALPLUSF INHALER 250/25SEROFLO 250 HFA INHALER | $55.7M | 44 | 76.5% |
| 2 | HETERO LABS LIMITED SAFLU 250 INHALER (SALMETEROLFLUSACORT SALMETEROL+FLUTICASONE PROPIONATE INHALERSAFLU 250 INHALER | $6.4M | 4 | 8.8% |
| 3 | MEDISPRAY LABORATORIES PRIVATE LIMITED SEROFLO 250 HFA INHALERSEROFLO 250 HFA INHALER SALMETEROL XINASEROFLO 125 HFA INHALER | $3.1M | 1 | 4.3% |
| 4 | ZYDUS LIFESCIENCES LIMITED SEROFLO 500 DP CAPS ( SALMETEROL XINAFOASEROFLO 500 DP CAPS (SALMETEROL XINAFOATSEROFLO 250 DP CAPS ( SALMETEROL XINAFOA | $1.1M | 5 | 1.5% |
| 5 | VAMSI PHARMA PRIVATE LIMITED FLUTICASONE & SALMETEROL INHALATION POWDERSEROFLO 250 MCG INHALER NOSSEROFLO 250 MCG INHALER (SALMETEROL XINA | $1.1M | 2 | 1.5% |
| 6 | SAVA HEALTHCARE LIMITED | $614.7K | 4 | 0.8% |
| 7 | GLENMARK PHARMACEUTICALS LIMITED | $526.5K | 6 | 0.7% |
| 8 | SUN PHARMACEUTICAL INDUSTRIES LIMITED SEROFLO 250 HFA INHALERSEROFLO 250 HFA INHALER SALMETEROL XINASEROFLO 125 HFA INHALER | $492.8K | 3 | 0.7% |
| 9 | MIDAS CARE PHARMACEUTICALS PVT LTD SEROFLO 500 DP CAPS ( SALMETEROL XINAFOASEROFLO 500 DP CAPS (SALMETEROL XINAFOATSEROFLO 250 DP CAPS ( SALMETEROL XINAFOA | $439.5K | 4 | 0.6% |
| 10 | LLOYD LABORATORIES PRIVATE LIMITED | $392.8K | 1 | 0.5% |
| 11 | KOPRAN LIMITED | $392.3K | 1 | 0.5% |
| 12 | CADILA HEALTHCARE LIMITED | $307.6K | 2 | 0.4% |
| 13 | POLLOMI PHARMACEUTICAL PRIVATE LIMITED | $245.0K | 1 | 0.3% |
| 14 | PRIME PHARMACEUTICALS PRIVATE LIMITED | $215.3K | 2 | 0.3% |
| 15 | MIDAS CARE PHARMACEUTICALS PRIVATE LIMITED SEROFLO 500 DP CAPS ( SALMETEROL XINAFOASEROFLO 500 DP CAPS (SALMETEROL XINAFOATSEROFLO 250 DP CAPS ( SALMETEROL XINAFOA | $184.2K | 2 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Salmeterol exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla has received FDA approvals for various products and holds WHO-GMP and EU G |
| HETERO LABS LIMITED | Approved | Yes | Yes | Multiple | Hetero Labs has FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| MEDISPRAY LABORATORIES PRIVATE LIMITED | Voluntary Action Indicate | Yes | Yes | Not specified | Medispray, a subsidiary of Cipla, received a VAI classification from the FDA in |
| ZYDUS LIFESCIENCES LIMITED | Approved | Yes | Yes | Multiple | Zydus Lifesciences has FDA approvals and holds WHO-GMP and EU GMP certifications |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | Multiple | Sun Pharma has FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| GLENMARK PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Glenmark has FDA approvals and holds WHO-GMP and EU GMP certifications. |
| SAVA HEALTHCARE LIMITED | Approved | Yes | Yes | Not specified | Sava Healthcare has FDA approval and maintains WHO-GMP and EU GMP certifications |
| MIDAS CARE PHARMACEUTICALS PVT LTD | Approved | Yes | Yes | Not specified | Midas Care has FDA approval and holds WHO-GMP and EU GMP certifications. |
| LLOYD LABORATORIES PRIVATE LIMITED | Approved | Yes | Yes | Not specified | Lloyd Laboratories has FDA approval and maintains WHO-GMP and EU GMP certificati |
| VAMSI PHARMA PRIVATE LIMITED | Approved | Yes | Yes | Not specified | Vamsi Pharma has FDA approval and holds WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 10 leading Salmeterol exporters from India. 9 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Salmeterol sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. This prominence is supported by a robust infrastructure and a concentration of pharmaceutical companies specializing in active pharmaceutical ingredients (APIs). The city's pharmaceutical sector has been a significant contributor to India's pharmaceutical exports, with a substantial portion of bulk drugs being produced in this region.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts numerous companies specializing in the production of finished dosage forms, including tablets, capsules, and injectables. The presence of established firms like Alembic Pharmaceuticals in Vadodara underscores the area's significance in the formulations segment. Alembic Pharmaceuticals, headquartered in Vadodara, manufactures and markets a wide range of pharmaceutical products, including APIs and formulations, and has a notable presence in the macrolide anti-infective drug segment.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. This region's strategic coastal location facilitates efficient international shipping, making it a hub for pharmaceutical exports. Companies in this area benefit from well-developed logistics and proximity to major ports, enhancing their export capabilities. The region's infrastructure supports a seamless supply chain, crucial for timely delivery to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the area, contributing to its rapid industrial growth. The region's focus on pharmaceutical production has bolstered its position as a key player in the industry.
5Sourcing Recommendations
- Diversify Supplier Base: While CIPLA LIMITED dominates Salmeterol exports, consider engaging with other suppliers such as HETERO LABS LIMITED and MEDISPRAY LABORATORIES PRIVATE LIMITED to mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad's expertise in bulk drug production for sourcing APIs and Ahmedabad-Vadodara's capabilities in formulations to optimize procurement strategies.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to ensure efficient and timely international shipments.
- Evaluate Cost Benefits: Assess the financial advantages of sourcing from the Baddi-Nalagarh region, considering the tax incentives and manufacturing capabilities available.
By strategically engaging with these regional clusters, companies can enhance their supply chain resilience and capitalize on India's diverse pharmaceutical manufacturing landscape.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Salmeterol exporters from India
CIPLA LIMITED — Cipla acquires Ivia Beaute's personal care brands to expand consumer wellness portfolio
Cipla Limited acquired the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, with an additional ₹110 crore as milestone-based consideration. This acquisition includes brands like Astaberry and Ikin, enhancing Cipla's consumer health vertical. IMPACT: This strategic move diversifies Cipla's portfolio but is not directly related to Salmeterol exports.
Impact: This strategic move diversifies Cipla's portfolio but is not directly related to Salmeterol exports.
ZYDUS LIFESCIENCES LIMITED — Zydus Lifesciences acquires Amplitude Surgical to enter medical devices market
Zydus Lifesciences acquired 85.6% of France-based Amplitude Surgical for €256.8 million, marking its entry into the medical devices segment, particularly in lower-limb orthopedic implants. IMPACT: This acquisition diversifies Zydus's offerings but does not impact Salmeterol exports.
Impact: This acquisition diversifies Zydus's offerings but does not impact Salmeterol exports.
ZYDUS LIFESCIENCES LIMITED — Zydus Lifesciences acquires 50% stake in Sterling Biotech Limited
Zydus Lifesciences, through its subsidiary, acquired a 50% equity stake in Sterling Biotech Limited, a company specializing in gelatin, di-calcium phosphate, and select active pharmaceutical ingredients. IMPACT: This acquisition enhances Zydus's biotech capabilities but does not directly affect Salmeterol exports.
Impact: This acquisition enhances Zydus's biotech capabilities but does not directly affect Salmeterol exports.
Common Questions — Salmeterol Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which salmeterol supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 1,265 recorded shipments worth $55.7M. HETERO LABS LIMITED (139 shipments) and MEDISPRAY LABORATORIES PRIVATE LIMITED (22 shipments) are also established high-volume exporters.
Q How many salmeterol manufacturers are there in India?
India has 148 active salmeterol exporters with a combined export market of $72.8M across 7,006 shipments to 90 countries. The top 5 suppliers hold 92.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for salmeterol from India?
Average FOB unit price: $18.14 per unit, ranging from $0.01 to $3871.76. Average shipment value: $10.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 148 verified Indian exporters of Salmeterol ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 7,006 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 90 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
7,006 Verified Shipments
148 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists